Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.52 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.47 |
| ▸ | TRPA1 | O75762 | 4/20 | 0.45 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.45 |
| ▸ | GRM5 | P41594 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 2/20 | 0.39 |
| ▸ | MAOB | P27338 | 2/20 | 0.39 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.39 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.39 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.39 |
| ▸ | SNCA | P37840 | 1/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8975327 | 0.78 | HTR2A (0.46) | TAAR1TSHR | |
| SCHEMBL18244911 | 0.77 | TAAR1 (0.52) | TAAR1AOC3TRPA1RIPK1GRM5 | |
| SCHEMBL1553978 | 0.77 | TAAR1 (0.52) | TAAR1AOC3TRPA1RIPK1GRM5 | |
| SCHEMBL703312 | 0.77 | TAAR1 (0.52) | TAAR1AOC3TRPA1RIPK1GRM5 | |
| SCHEMBL2760210 | 0.77 | TAAR1 (0.52) | TAAR1AOC3TRPA1RIPK1GRM5 | |
| SCHEMBL17593126 | 0.76 | TAAR1 (0.50) | TAAR1AOC3TRPA1RIPK1GRM5 | |
| SCHEMBL3560379 | 0.75 | RIPK1 (0.48) | TAAR1AOC3TRPA1RIPK1CYP1A2 | |
| SCHEMBL5794231 | 0.75 | TAAR1 (0.55) | TAAR1AOC3CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL6014574 | 0.74 | TAAR1 (0.54) | TAAR1AOC3TRPA1RIPK1GRM5 | |
| SCHEMBL18244887 | 0.74 | GRM5 (0.50) | TAAR1AOC3TRPA1RIPK1GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106414461-B | Borate-based generated base alkaline agent and alkali reactive composition containing the generated base alkaline agent | 富士胶片和光纯药株式会社 | 2018-09-11 | — | — | CN | disclosed |
| CN-106414461-A | BORATE-BASED BASE GENERATOR, AND BASE-REACTIVE COMPOSITION COMPRISING SUCH BASE GENERATOR | 和光纯药工业株式会社 | 2017-02-15 | — | — | CN | disclosed |
| US-20150368278-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY PHARMACEUTICALS, INC. (US) | 2015-12-24 | — | — | US | disclosed |
| US-8957049-B2 | Inhibitors of fatty acid amide hydrolase | INFINITY PHARMACEUTICALS, INC. (US) | 2015-02-17 | — | — | US | disclosed |
| CN-102046179-B | Inhibitors of fatty acid amide hydrolase | INFINITY PHARMACEUTICALS INC | 2015-01-14 | — | — | CN | disclosed |
| US-20110172186-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY PHARMACEUTICALS, INC. | 2011-07-14 | — | — | US | disclosed |
| CN-102046179-A | Inhibitors of fatty acid amide hydrolase | INFINITY PHARMACEUTICALS INC | 2011-05-04 | — | — | CN | disclosed |
| EP-2282742-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | Infinity Pharmaceuticals, Inc. (US) | 2011-02-16 | — | — | EP | disclosed |
| WO-2009126691-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY PHARMACEUTICALS, INC (US) | 2009-10-15 | — | — | WO | disclosed |
| EP-1677789-A1 | ALKYNES I | AstraZeneca AB (SE) | 2006-07-12 | — | — | EP | disclosed |
| WO-2005044266-A1 | ALKYNES I | ASTRAZENECA AB (SE) | 2005-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172186-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | FAAH, FAAH2, ASAH1 | TAAR1 597/4885AOC3 931/4885TRPA1 964/4885 |
| US-20150368278-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | FAAH, FAAH2, ASAH1 | TAAR1 597/4885AOC3 931/4885TRPA1 964/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.